Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine

Journal of Analytical Toxicology

Volumn 22, Issue 1, 1998, Pages 50-54

  Fraser, Albert D ^a,b   Howell, Pamela ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG ABUSE; DRUG DETERMINATION; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; NORTH AMERICA; ORAL DRUG ADMINISTRATION; PRESCRIPTION; QUANTITATIVE ASSAY; STANDARD; URINALYSIS;

EID: 0031937634     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/22.1.50     Document Type: Article

References (14)

1. A.D. Fraser. Urinary screening for alprazolam, triazolam and their metabolites with the EMIT® dau™ benzodiazepine assay. J. Anal. Toxicol. 11 : 263-266 (1987).
2. A.D. Fraser and R. Meatherall. Comparative evaluation of five immunoassays for the analysis of alprazolam and triazolam metabolites in urine: effect of lowering the screening and CC-MS cut-off values. J. Anal. Toxicol. 20: 217-223 (1996).
3. A. Poklis. An evaluation of EMIT®-dau benzodiazepine metabolite assay for urine drug screening. J. Anal. Toxicol. 5: 174-176 (1981).
4. L. Miller. Oxaprozin: a once daily nonsteroidal anti-inflammatory drug. Clin. Pharm. 11: 591-603 (1992).
5. V. Hale and E.D. Bashaw. Pharmacokinetics of oxaprozm. Clin. Pharm. 12: 255-256 (1993).
6. The top 200 drugs. American Druggist 213(2): 19-24 (1996).
7. The top 200 drugs. American Druggist 214(2): 30-37 (1997).
8. P.D. Camara, L. Audette, K. Velletri, P. Breitenbecher, M. Rosner, and W.C. Griffiths. False positive immunoassay results for urine benzodiazepine in patients receiving oxaprozin (Daypro™). Clin. Chem. 45: 115-116 (1995).
9. T. Matuch-Hite, P. Jones, Jr., and J. Moriarity. Interference of oxaprozin with benzodiazepines via enzyme immunoassay technique. J. Anal. Toxicol. 19: 130 (1995).
10. Abbott Benzodiazepine Assay on the TDxFLx analyzer (List No. 9674). Abbott Laboratories, Diagnostics Division, Abbott Park, IL, January (1996).
11. EMIT dau Benzodiazepine Assay Package Insert. Behring Diagnostics, San Jose, CA, November (1995).
12. CEDIA DAU Benzodiazepine Assay Package Insert. Microgenics, a Boehringer Mannheim Company, Concord, CA, November (1995).
13. Clinical research report. Profile of oxaprozin versus piroxicam: pharmacokinetic evaluations of single dose and pharmacokinetic and pharmacodynamic evaluations of multiple dose administration in young healthy subjects versus healthy elderly subjects with osteoarthritis, S65-90-02-004. Searle Pharmaceutical Co., Skokie, IL, April 1994.
14. R. Meatherall and J. Dai. False positive EMIT II opiates from ofloxacin. Ther. Drug Monit. 19: 98-99 (1997).